

Lynk Pharmaceuticals gets clinical approval in China for Class I New Drug LNK01004

22 April 2022 | News

LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psoriasis



Lynk Pharmaceuticals, an innovative clinical stage company, has announced that its Class I innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for clinical trials for the treatment of psoriasis.

LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psoriasis, and thus potentially offer maximal efficacy. In preclinical studies, LNK01004 showed a skin-restricted drug exposure. The drug is mainly distributed in the site of action– the skin tissues, with very low systemic drug exposure, thus, avoiding potential safety concerns due to immune suppression resulted from systemic drug exposure. LNK01004 demonstrated good efficacy and safety in animal disease models.

Dr. Zhao-Kui (ZK) Wan, founder and CEO of Lynk Pharmaceuticals, said, "LNK01004 is the fourth novel drug candidate developed and approved for clinical studies by the company to date, and can be used for the treatment of psoriasis with dermal administration. According to statistics, there are 156 million patients worldwide and 6 million patients in China. Patients often require long-term treatment, which in turn places high demands on the efficacy and safety of the drug. There are high unmet medical needs for psoriasis patients. LNK01004 demonstrated good efficacy and safety in preclinical studies and is expected to provide psoriasis patients with a new safe and effective drug option."